This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Insulet (PODD) Stock Moves -0.97%: What You Should Know
by Zacks Equity Research
Insulet (PODD) closed at $280.36 in the latest trading session, marking a -0.97% move from the prior day.
Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Insulet (PODD) could produce exceptional returns because of its solid growth attributes.
Insulet (PODD) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Insulet (PODD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Teladoc Health (TDOC) Down 8.1% Since Q4 Earnings Release
by Zacks Equity Research
Teladoc Health's (TDOC) fourth-quarter results bear the brunt of escalating expenses. Management expects 2023 revenues within $2,550-$2,675 million, way higher than the 2022 figure.
Insulet (PODD) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Insulet's (PODD) Q4 performance benefits from record quarterly U.S. and Total Omnipod new customer starts.
Insulet (PODD) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 129.17% and 11.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Insulet (PODD) closed the most recent trading day at $298.61, moving +1.28% from the previous trading session.
Insulet (PODD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
In Drug Delivery, Insulet (PODD) is expected to have faced higher manufacturing costs in Q4.
Insulet (PODD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Insulet (PODD) closed at $289.36 in the latest trading session, marking a -0.96% move from the prior day.
Insulet (PODD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Insulet (PODD) closed the most recent trading day at $290.53, moving +1.12% from the previous trading session.
Boston Scientific (BSX) Lags Q4 Earnings Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of -4.26% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Insulet (PODD) closed at $286.13, marking a -1.23% move from the previous day.
Insulet (PODD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Insulet (PODD) closed the most recent trading day at $289.70, moving -0.68% from the previous trading session.
Insulet (PODD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Insulet (PODD) closed at $292.38 in the latest trading session, marking a +1.11% move from the prior day.
Insulet (PODD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Insulet (PODD) closed the most recent trading day at $305.89, moving -0.13% from the previous trading session.
Insulet (PODD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Insulet (PODD) closed the most recent trading day at $296.27, moving +1.35% from the previous trading session.
Insulet's (PODD) Omnipod Sales Aid, Costs Continue to Rise
by Zacks Equity Research
Insulet (PODD) progresses well with respect to its four-pillar strategy, wherein the first two pillars include expanding access and awareness, and delivering consumer-focused innovation.
Is Nuveen ESG MidCap Growth ETF (NUMG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NUMG
Insulet (PODD) Q3 Earnings Beat Estimates, '22 Sales View Up
by Zacks Equity Research
Insulet's (PODD) performance benefits from record quarterly U.S. and Total Omnipod new customer starts.
Insulet (PODD) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 164.71% and 9.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Insulet (PODD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 7th
by Zacks Equity Research
GIII, PODD and LU have been added to the Zacks Rank #5 (Strong Sell) List on October 7, 2022.
3 Reasons to Hold Insulet (PODD) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Insulet (PODD) on Omnipod's continued market access expansion.
Insulet (PODD) Q2 Earnings Miss Estimates, '22 Sales View Up
by Zacks Equity Research
Insulet (PODD) posts better-than-expected revenues in Q2 with robust contributions from Total Omnipod.